ID 02938515 Solicited Manuscript "Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching" includes the various items that are listed in the statement

STROBE Statement-checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		(b) Provide in the abstract an informative and balanced summary of what was done
		and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
<b>D</b> ectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
		exposure, follow-up, and data collection
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of
		selection of participants. Describe methods of follow-up
		Case-control study—Give the eligibility criteria, and the sources and methods of
		case ascertainment and control selection. Give the rationale for the choice of cases
		and controls
		Cross-sectional study—Give the eligibility criteria, and the sources and methods of
		selection of participants
		(b) Cohort study—For matched studies, give matching criteria and number of
		exposed and unexposed and unexposed and unexposed and unexposed
		Case-control study-For matched studies, give matching criteria and the number of
		controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
		modifiers. Give diagnostic criteria, if applicable
Data sources/	8*	For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there
		is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Onantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
		describe which groupings were chosen and why
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		(b) Describe any methods used to examine subgroups and interactions
		(c) Explain how missing data were addressed
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed
		Case-control study-If applicable, explain how matching of cases and controls was
		addressed
		Cross-sectional study-If applicable, describe analytical methods taking account of
		sampling strategy
		(e) Describe any sensitivity analyses

Continued on next page

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study-eg numbers potentially eligible,
		examined for eligibility, confirmed eligible, included in the study, completing follow-up, and
		analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information
data		on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Cohort study-Report numbers of outcome events or summary measures over time
		Case-control study-Report numbers in each exposure category, or summary measures of
		exposure
		Cross-sectional study-Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their
		precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and
		why they were included
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful
		time period
Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions, and sensitivity
		analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.
		Discuss both direction and magnitude of any potential bias
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity
		of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other information	on	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable,
		for the original study on which the present article is based

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.